SCHEMBL6329545

SCHEMBL6329545

CN1CCN(C(CN2CCN(CCCCc3cccc4ccccc34)CC2)c2ccc([N+](=O)[O-])cc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MC4R P32245 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6321623 0.86 MC4R (1.00) MC4R
SCHEMBL6322785 0.86 MC4R (1.00) MC4R
Hydrochloric Acid SCHEMBL6322971 0.85 MC4R (0.98) MC4R
Hydrochloric Acid SCHEMBL6321736 0.85 MC4R (0.98) MC4R
SCHEMBL6321344 0.84 MC4R (1.00) MC4R
SCHEMBL6321892 0.79 MC4R (1.00) MC4R
SCHEMBL6324577 0.75 MC4R (0.77) MC4R
Hydrochloric Acid SCHEMBL6321995 0.75 MC4R (0.98) MC4R
SCHEMBL6323922 0.74 MC4R (0.80) MC4R
SCHEMBL6329105 0.74 MC4R (0.72) MC4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949552-B2 Remedial agent for anxiety neurosis or depression and piperazine derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2005-09-27 US disclosed
US-20030186992-A1 Remedial agent for anxiety neurosis or depression and piperazine derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2003-10-02 US disclosed
EP-1295608-A1 REMEDIAL AGENT FOR ANXIETY NEUROSIS OR DEPRESSION AND PIPERAZINE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2003-03-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186992-A1 Remedial agent for anxiety neurosis or depression and piperazine derivative CNR1, HTR4, TPH1 MC4R 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.